Physician profile
Aaron Avni
NPI 1134155682
$17,566.53
in general payments reported to CMS, 2019-2025
27 companies · $3,171 in 2025
The $3,171 reported for 2025 was more than what 92% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,381 · 2020: $706 · 2021: $1,693 · 2022: $2,887 · 2023: $2,521 · 2024: $4,208 · 2025: $3,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,687 · Long Term Medical Supply Or Device Loan: $195 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,686.68 |
| Long Term Medical Supply Or Device Loan | $195.00 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,174.13 | 2019-2025 | Clareon, Hydrus Microstent, Simbrinza |
| Abbvie INC. | $3,017.71 | 2022-2025 | Durysta, Alphagan P, Lumigan |
| Bausch & Lomb Americas INC. | $1,944.12 | 2022-2025 | Envista Mx60 Iol, Miebo, Xiidra |
| Allergan, INC. | $1,518.06 | 2019-2022 | |
| Ocular Therapeutix, INC. | $1,083.22 | 2019-2025 | Dextenza |
| Oyster Point Pharma, INC. | $1,032.13 | 2022-2025 | Tyrvaya, Ryzumvi |
| Glaukos Corporation | $727.82 | 2019-2025 | Idose, Idosetr, Istent Trabecular Micro-Bypass System Model Is3 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $713.46 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $513.50 | 2019-2020 | |
| Rxsight INC | $431.85 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| New World Medical,INC. | $407.40 | 2022-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Kala Pharmaceuticals, INC. | $343.42 | 2019-2021 | |
| Shire North American Group INC | $336.53 | 2019 | |
| Biotissue Holdings INC. | $323.60 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $308.78 | 2024-2025 | Xdemvy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $286.70 | 2024-2025 | Tepezza |
| Novartis Pharmaceuticals Corporation | $277.33 | 2020-2023 | |
| Dompe US, INC. | $225.13 | 2022-2025 | Oxervate |
| Sight Sciences, INC. | $206.07 | 2022 | |
| Horizon Therapeutics Plc | $167.03 | 2023 | Tepezza |
| Ivantis, INC | $148.97 | 2021 | |
| Harrow Eye, LLC | $103.24 | 2024-2025 | Vevye, Ilevro |
| Rayner Intraocular Lenses Limited | $95.94 | 2024-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Ani Pharmaceuticals, INC. | $61.22 | 2025 | Purified Cortrophin Gel |
| Sun Pharmaceutical Industries INC. | $56.55 | 2024-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $48.65 | 2023-2025 | Tecnis Iol, Tecnis Simplicity |
| Eyevance Pharmaceuticals LLC | $13.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Avni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.